Belimumab in systemic lupus erythematosus

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Vilas Boas, Andreia ^a   Morais, Sandra A ^a   Isenberg, David A ^b  

^a HOSPITAL PEDRO HISPANO   (Portugal)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193126     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000011     Document Type: Review

References (63)

1. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384:1878-88.
2. Murpgy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet 2013;382:809-18.
3. Johnson AE, Gordon C, Palmer RG, et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis Rheum 1995;38:551-8.
4. Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 2009;18:869-74.
5. Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev 2014;13:1094-101.
6. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007;56:1251-62.
7. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
8. Bertsias G, Ioannidis JP, Boletis J, et al., Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
9. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
10. Devilliers H, Amoura Z, Besancenot JF, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford) 2014. Published Online First: 30 Oct 2014. doi:10.1093/rheumatology/keu410
11. Moser KL, Kelly JA, Lessard CJ, et al. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009;10:373-9.
12. Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1228-33.
13. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.
14. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011;13:228-38.
15. Shlomchik MJ, Madaio MP, Ni D, et al. The role of B cells in lpr/ lpr-induced autoimmunity. J Exp Med 1994;180:1295-306.
16. Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160:51-9.
17. Chan O, Hannum L, Haberman A, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
18. Holroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric 2009;12:378-86.
19. Smith-Bouvier DL, Divekar AA, Sasidhar M, et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008;205:1099-108.
20. Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010;13:3-11.
21. Batten M, Groom J, Cachero T, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-65.
22. Mackay F, Schneider P, Rennert P, et al. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64.
23. Vincent FB, Morand E, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-73.
24. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-8.
25. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updates perspective. Immunol Rev 2010;237:264-83.
26. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008;180:3655-9.
27. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
28. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006;116:724-34.
29. Chu VT, Enghard P, Schuürer S, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009;60:2083-93.
30. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
31. Vaux D. The buzz about BAFF. J Clin Invest 2002;109:17-18.
32. Hahn B. Belimumab for systemic lupus erythematosus. N Eng J Med 2014;368:1528-35.
33. Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 2014;18:473-89.
34. Gottenberg JE, Lorenzo N, Sordet C, et al. When biologics should be used in systemic lupus erythematosus? Presse Med 2014;43(6 Pt 2):e181-5.
35. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
36. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
37. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
38. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
39. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
40. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
41. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012;39:1632-40.
42. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8.
43. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
44. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343-9.
45. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300-9.
46. Human Genome Sciences. Arthritis Advisory Committee Meeting briefing document for the 16 November meeting. FDA [online]. 2010. http://www.fda.gov/download/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/ UCM233581.pdf
47. ClinicalTrials.gov. Identifier NCT01597492, a phase 4, multi-center, randomized, open-label study to evaluate the effect of BENLYSTA™ (Belimumab; HGS1006) on vaccine responses in subjects with systemic lupus erythematosus (SLE). https://clinicaltrials.gov/ct2/ show/record/NCT01597492
48. ClinicalTrials.gov Identifier:NCT01639339. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of belimumab plus standard of care versus placebo plus standard of care in adult subjects with active lupus nephritis. https:// clinicaltrials.gov/ct2/show/NCT01639339
49. ClinicalTrials.gov Identifier:NCT01632241. A phase 3/4, multi-center, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab (HGS1006) in adult subjects of black race with systemic lupus erythematosus (SLE). https://clinicaltrials.gov/ct2/show/NCT01632241
50. ClinicalTrials.gov. Identifier NCT01649765, a multi-center, randomized, placebo-controlled trial to evaluate the safety, efficacy, and pharmacokinetics of belimumab, a human monoclonal anti-BLyS antibody, plus standard therapy in pediatric patients with systemic lupus erythematosus (PLUTO). http://clinicaltrials.gov/ct2/ show/NCT01649765
51. ClinicalTrials.gov Identifier:NCT01705977. A randomized, double-blind, placebo-controlled 52-week study to assess adverse events of special interest in adults with active, autoantibody-positive systemic lupus erythematosus receiving belimumab. https:// clinicaltrials.gov/ct2/show/NCT01705977
52. ClinicalTrials.gov Identifier: NCT02119156. An open-label, non-randomized, 52-week study to evaluate treatment holidays and rebound phenomenon after treatment with belimumab 10 mg/kg in systemic lupus erythematosus subjects. https://clinicaltrials.gov/ct2/ show/NCT02119156
53. ClinicalTrials.gov Identifier: NCT01345253. GSK1550188, a 52 week study of belimumab versus placebo in the treatment of subjects with systemic lupus erythematosus (SLE) located in Northeast Asia. https://clinicaltrials.gov/ct2/show/NCT01345253
54. ClinicalTrials.gov Identifier: NCT01597622. BEL114333, a multicenter, continuation study of belimumab in subjects with systemic lupus erythematosus (SLE) who completed the Phase III Study BEL113750 in Northeast Asia or completed the open-label extension of HGS1006-C1115 in Japan. https://clinicaltrials.gov/ct2/ show/NCT01597622
55. ClinicalTrials.gov Identifier: NCT00724867. A multi-center, continuation trial of belimumab (HGS1006, LymphoStat-B™), a fully human monoclonal anti-BLyS antibody, in subjects with systemic lupus erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 in the United States. https://clinicaltrials.gov/ct2/ show/NCT00724867
56. ClinicalTrials.gov Identifier: NCT00712933. A multi-center, continuation trial of belimumab (HGS1006, LymphoStat-B™) a fully human monoclonal anti-BLyS antibody in subjects with systemic lupus erythematosus (SLE) who completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057. https://clinicaltrials.gov/ct2/ show/NCT00712933
57. ClinicalTrials.gov Identifier: NCT00583362. A multi-center, open-label, continuation trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in subjects with systemic lupus erythematosus (SLE) who completed the Phase 2 Protocol LBSL02. https:// clinicaltrials.gov/ct2/show/NCT00583362
58. ClinicalTrials.gov Identifier: NCT01484496. A phase 3, multi-center, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab (HGS1006) administered subcutaneously (SC) to subjects with systemic lupus erythematosus (SLE). https://clinicaltrials.gov/ct2/show/NCT01484496
59. ClinicalTrials.gov Identifier: NCT01729455. A 5-year Prospective Observational Registry to assess adverse events of interest and effectiveness in adults with active, autoantibody-positive systemic lupus erythematosus treated with or without BENLYSTA™ (belimumab). https://clinicaltrials.gov/ct2/show/NCT01729455
60. ClinicalTrials.gov Identifier: NCT01532310. Belimumab (BENLYSTA®) Pregnancy Registry (BPR)-Prospective Cohort Study of pregnancy outcomes following Benlysta exposure within 4 months prior to and/or during pregnancy. https://clinicaltrials.gov/ct2/ show/NCT01532310
61. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
62. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. Arthritis Rheum 2012;64:1215-26.
63. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672-9.